(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 38.93% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Trisalus Life Sciences's revenue in 2026 is $45,151,000.On average, 9 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,928,700,402, with the lowest TLSI revenue forecast at $3,604,818,496, and the highest TLSI revenue forecast at $4,332,219,371. On average, 6 Wall Street analysts forecast TLSI's revenue for 2027 to be $5,568,831,511, with the lowest TLSI revenue forecast at $4,964,166,123, and the highest TLSI revenue forecast at $5,947,705,292.
In 2028, TLSI is forecast to generate $7,476,933,057 in revenue, with the lowest revenue forecast at $6,782,331,125 and the highest revenue forecast at $7,950,218,750.